©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Aug 27, 2024; 16(8): 2365-2368
Published online Aug 27, 2024. doi: 10.4240/wjgs.v16.i8.2365
Published online Aug 27, 2024. doi: 10.4240/wjgs.v16.i8.2365
Immunotherapy for gastric cancer and liver metastasis: Is it time to bid farewell
Ahmed Dehal, Department of Clinical Sciences, Kaiser Permanente School of Medicine, Panorama, CA 91402, United States
Author contributions: Dehal A designed and wrote the paper.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Ahmed Dehal, FACS, FRCS, MD, Associate Professor, Surgical Oncologist, Department of Clinical Sciences, Kaiser Permanente School of Medicine, 13652 Cantara Street, Panorama, CA 91402, United States. ahmed.n.dehal@kp.org
Received: March 8, 2024
Revised: May 20, 2024
Accepted: June 5, 2024
Published online: August 27, 2024
Processing time: 160 Days and 17.7 Hours
Revised: May 20, 2024
Accepted: June 5, 2024
Published online: August 27, 2024
Processing time: 160 Days and 17.7 Hours
Core Tip
Core Tip: The prognosis of patients with gastric cancer and liver metastasis is abysmal. Palliative chemotherapy is associated with a limited survival benefit yet is very toxic. Immunotherapy is considered an emerging promising therapy with some remarkable results. There has been a growing body of literature from animal and human studies that question the efficacy of immunotherapy in these patients. In this article, we discuss this issue and provide a balanced appraisal of the literature.